Understanding Study Drug Discontinuation Through EUCLID

Understanding Study Drug Discontinuation Through EUCLID

IntroductionDisparities in the care and outcomes of peripheral artery disease (PAD) have been well-established. In part this is due to disparities in enrollment of PAD trial cohorts. However, less attention has been paid to non-random protocol non-adherence after enrollment, which may lead to inaccu...

Full description

Bibliographic Details
Main Authors: E. Hope Weissler, Hillary Mulder, Frank W. Rockhold, Iris Baumgartner, Lars Norgren, Juuso Blomster, Brian G. Katona, F. Gerry R. Fowkes, Kenneth Mahaffey, Marc Bonaca, Manesh R. Patel, W. Schuyler Jones
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
peripheral artery disease (PAD)
clinical trial
protocol deviation
disparities (health
antiplatelet therapy)
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.947645/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.947645/full

Similar Items